Cathelicidin LL-37 in bronchoalveolar lavage and epithelial lining fluids from COPD patients and healthy individuals

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 4, 2012, Pages 617-625

  Golec, Marcin ^a   Reichel, C ^b   Lemieszek, M ^a   Mackiewicz, B ^c   Buczkowski, J ^c   Sitkowska, J ^a   Skorska C ^a   Dutkiewicz, J ^a   Milanowski, J ^a,c   Ziesche, R ^d  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antimicrobial peptides; BALF; Cathelicidin; COPD; Innate immunity

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ADULT; AGED; ANTIBODY AFFINITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; FEMALE; GROWTH INHIBITION; HUMAN; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM; LUNG FLUID; LUNG LAVAGE; MALE; MASS SPECTROMETRY; NONHUMAN; CHEMISTRY; CROSS-SECTIONAL STUDY; IMMUNOLOGY; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; BRONCHOALVEOLAR LAVAGE FLUID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNITY, INNATE; LUNG; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84876586828     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Calderón-Larrañaga A, Carney L, Soljak M, et al. Association of population and primary healthcare factors with hospital admission rates for chronic obstructive pulmonary disease in England: national cross-sectional study. Thorax 2010; 147058.
2. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 2007; 4:512-21. (Pubitemid 47547845)
3. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Ann Rev Pathol 2009; 4:435-59.
4. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-38.
5. Golec M, Reichel C, Mackiewicz B, et al. Cathelicidin LL-37, granzymes, TGF-beta1 and cytokines levels in induced sputum from farmers with and without COPD. Ann Agric Environ Med 2009; 16:289-97.
6. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30:131-41.
7. Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM. Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 2005; 97:171-79. (Pubitemid 40326948)
8. Pütsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002; 360:1144-49. (Pubitemid 35246490)
9. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005; 27:1337-47. (Pubitemid 41805626)
10. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95:9541-46. (Pubitemid 28506267)
11. Golec M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. Ann Agric Environ Med 2007, 14:1-4. (Pubitemid 47035650)
12. Shaykhiev R, Beisswenger C, Kandier K, Senske J, Puchner A, Damm T, Behr J, Bals R. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 2005; 289:842-8.
13. Xiao W, Hsu YP, Ishizaka A, Kirikae T, Moss RB. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 2005; 128:2316-26. (Pubitemid 41507575)
14. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-46. (Pubitemid 38807371)
15. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease Updated 2010.
16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993; 16:5-40.
17. Agerberth B, Grunewald J, Castanos-Velez E, Olsson B, Jörnvall H, Wigzell H, Eklund A, Gudmundsson GH. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999; 160:283-90. (Pubitemid 29326101)
18. Sabounchi-Schütt F, Aström J, Hellman U, Eklund A, Grunewald J. Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. Eur Respir J 2003; 21:414-20. (Pubitemid 36336198)
19. Adams FH, Moss AJ, Fagan L. The tracheal fluid in the fetal lamb. Biol Neonat 1963; 5:151-58.
20. Theodore J, Robin ED, Gaudio R, Acevedo J. Transalveolar transport of large polar solutes (sucrose, insulin, and dextran). Am J Physiol 1975; 229:989-96.
21. Rennard S, Basset G, Lecossier D et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J Appl Physiol 1986; 60:532-38. (Pubitemid 16019939)
22. Taylor AE, Guyton AC, Bishop VS. Permeability of the alveolar membrane to solutes. Circ Res 1965; 16:353-62.
23. Bals R, Hiemstra PS. Antimicrobial peptides in COPD-basic biology and therapeutic applications. Curr Drug Targets 2006; 7:743-50. (Pubitemid 43827270)
24. Jiang Y, Xiao W, Zhang Y, Xing Y. Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease. Respirology 2010; 15:939-46.
25. Küpeli E, Karnak D, Beder S, Kayacan O, Tutkak H. Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients. Respiration 2008; 75:73-78.
26. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364:709-21. (Pubitemid 39140629)
27. Antoniou KM, Alexandrakis M, Tzanakis N, Tsiligianni I, Tzortzaki EG, Siafakas NM, Bouros DE. Induced sputum versus bronchoalveolar lavage fluid in the evaluation of patients with idiopathic pulmonary fibrosis. Respiration 2005; 72:32-8. (Pubitemid 40470275)
28. Amer LS, Bishop BM, van Hoek ML. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem Biophys Res Commun 2010; 396:246-51.
29. Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007; 12:81-7.
30. Nell MJ, Tjabringa GS, Wafelman AR, Verrijk R, Hiemstra PS, Drijfhout JW, Grote JJ. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 2006; 27:649-60.